Результаты поиска

Clinical applications of palifermin: amelioration of oral mucositis and other potential indications.

Mucositis is one of the most significant toxicities in cancer patients undergoing cytotoxic treatment. It can have a negative impact on both quality of life and health economics. Severe oral mucositis can contribute to hospitalization, need for narcotic analgesics, total parentral nutrition, suboptimal delivery of anti-neoplastic treatment, and morbidity and mortality. Palifermin, a recombinant derivative of human keratinocyte growth factor, is the first active agent approved by the FDA for the prevention of severe oral mucositis in patients undergoing haematopoietic stem cell transplantation

Совпадение в полном тексте источника
… Sarcoma Doxorubicin is a very effective agent in the treatment of soft tissue sarcoma, and is often combined with ifosfamide or dacarbazine (AI or ADIC regimens). … Results of two consecutive trials of dose-intensive chemotherapy with doxorubicin and ifosfamide in patients with sarcomas. Amer J Clin Oncol. 1998;21:317–21. doi: 10.1097/00000421-199806000-00025. Vadhan-Raj S, Patel S, Bueso-Ramos CE, et al. …

Hypertension in Cardio-Oncology Clinic: an update on etiology, assessment, and management.

Hypertension is one of the most common comorbidity and the leading cause of cancer-related death in cancer patients. The prevalence of hypertension in cancer patients is much higher than that of the general population. In the older population of cancer patients, specific cancer treatments such as new tyrosine kinase inhibitors and Vascular endothelial growth factor inhibitor drugs give rise to hypertension in cancer patients; The aim of present study is to provide a detailed discussion etiologies of cancer treatment-induced hypertension and explore the most innovative diagnostic and management

Совпадение в полном тексте источника
… Hypertension was reported in pediatric cancer patients who were treated with ifosfamide [ 48 ]. Recent studies do not indicate hypertension as one of the complications in cancer treatment field [ 49 ]. … Cyclophosphamide [ 46 , 47 ] ifosfamide [ 48 ] Anthracycline [ 49 ] Cisplatin [ 51 ]. …

Preventive strategies for acute kidney injury in cancer patients.

Acute kidney injury (AKI) is a common complication of cancer that occurs in up to 50% of neoplastic patients during the natural history of their disease; furthermore, it has a huge impact on key outcomes such as overall prognosis, length of hospitalization and costs. AKI in cancer patients has different causes, either patient-, tumour- or treatment-related. Patient-related risk factors for AKI are the same as in the general population, whereas tumour-related risk factors are represented by compression, obstruction, direct kidney infiltration from the tumour as well by precipitation, aggregatio

Совпадение в полном тексте источника
… Among cytotoxic chemotherapeutic agents, the ones most commonly related to the development of AKI are cisplatin (CDDP), mitomycin-C (MM-C), gemcitabine, methotrexate (MTX), ifosfamide and pemetrexed. … Other chemotherapeutic agents Although gemcitabine, ifosfamide and pemetrexed are potentially nephrotoxic, no measures to prevent AKI from these agents have been established to date, except those general interventions used to prevent AKI in non-oncological patients. …

Nephrotoxicity in cancer treatment: An overview.

Anticancer drug nephrotoxicity is an important and increasing adverse drug event that limits the efficacy of cancer treatment. The kidney is an important elimination pathway for many antineoplastic drugs and their metabolites, which occurs by glomerular filtration and tubular secretion. Chemotherapeutic agents, both conventional cytotoxic agents and molecularly targeted agents, can affect any segment of the nephron including its microvasculature, leading to many clinical manifestations such as proteinuria, hypertension, electrolyte disturbances, glomerulopathy, acute and chronic interstitial n

Совпадение в полном тексте источника
… Class | Drugs | Nephrotoxicity | Mechanism of action Alkylating agents | Bendamustine; Cyclophosphamide; Ifosfamide; Melfalano; Nitrosureasnts | AKI; Hemorrhagic cystitis; Inflammatory lesion; SIADH; Hyponatremia; Fanconi's syndrome; Interstitial nephritis; Diabetes | Damage to proximal and distal tubular … Nephrotoxic effects of ifosfamide are most commonly reported in childhood. In one study, insufficiency renal was observed in more than 80% of patients. …

Review of Hematology-Oncology Emergencies for Internal Medicine Residents.

The prevalence of cancer continues to grow globally every year. With therapeutic advances over the recent decades, the prevalence of individuals living with cancer continues to increase. Internal medicine residents can see patients admitted to the hospital for cancer-related emergencies. Early identification and appropriate management of these emergencies have been shown to improve mortality and morbidity. In this article, we aim to review the recent updates in the management of commonly encountered oncologic emergencies in the practice of internal medicine residents. This review will cover sp

Совпадение в полном тексте источника
… Causes include SIADH secretion, brain metastasis, chemotherapy (cisplatin, cyclophosphamide, ifosfamide, vinca alkaloids, imatinib, and methotrexate), and adverse effects, including nausea and vomiting. … Commonly implicated chemotherapeutic agents are anthracyclines, topoisomerase inhibitors, vinorelbine, cyclophosphamide, ifosfamide,​ and taxanes [ 3 , 41 ]. …

Risk Factors for Bisphosphonate-Related Osteonecrosis of the Jaws in Bone Metastatic Breast and Prostate Cancer under Zoledronate Treatment: A Retrospective Analysis from 10 Years of Evaluation.

OBJECTIVE: This study aims to analyze the risk factors for BRONJ in patients taking zoledronic acid (ZA) for metastatic breast and prostate cancer. METHODS: For this, a retrospective, quantitative, observational cohort study was conducted using data on adverse effects in the oral cavity in patients during chemotherapy for treatment of solid tumors available in the electronic patient record system of the Haroldo Juaçaba Hospital/Ceará Cancer Institute in the period from 2010, to 2019. Data were tabulated in Excel and exported to SPSS v20.0 software for statistical analysis, with 95% confidence

Совпадение в полном тексте источника
… | | BRONJ | | Total | No | Yes | p-Value Chemotherapy drug | | | | Methotrexate | 22 (1.1%) | 18 (1.0%) | 4 (3.3%)* | 0.023 Doxorubicin | 538 (27.9%) | 500 (27.7%) | 38 (30.9%) | 0.452 Cyclophosphamide | 663 (34.4%) | 614 (34.1%) | 49 (39.8%) | 0.193 Ifosfamide | 3 (0.2%) | 2 (0.1%) | 1 (0.8% … 0.041 | 1.89 (1.03-3.48) Anastrozole | 0.816 | 1.06 (0.66-1.69) Tamoxifen | 0.665 | 0.89 (0.53-1.51) Fulvestrant | 0.945 | 0.98 (0.47-2.01) Exemestane | 0.967 | 1.02 (0.45-2.32) Leuprorelin | 0.057 | 0.14 (0.02-1.06) Methotrexate | *0.049 | 3.33 (1.01-11.03) Cyclophosphamide | 0.845 | 1.05 (0.67-1.63) Ifosfamide …

Normal Absolute Monocyte Count at the Time of Relapse is Associated with Improved Survival After First Salvage Therapy in Adult Patients with Early Relapsed B-Lineage Acute Lymphoblastic Leukemia.

BackgroundPeripheral monocytes, a key cell type for innate immunity, have been shown to be associated with survival in various types of hematological malignancies. However, no previous studies regarding the prognostic impact of peripheral absolute monocyte count (AMC) in early relapsed B-lineage acute lymphoblastic leukemia (B-ALL) have been reported.MethodsForty-nine cases of early relapsed adult B-ALL were reviewed. The upper (0.80 × 109/L) and lower limits (0.12 × 109/L) of the normal value for AMC were used as cut-off points. Kaplan-Meier curves and Log rank test were used for comparison o

Совпадение в полном тексте источника
… single agents, such as methotrexate, etoposide, and others, 7) miscellaneous treatment combinations, such as vindesine (or vinorelbine) and dexamethasone (or prednisone) alone (VP), or in combination with methotrexate (VPM), or mitoxantrone, teniposide, and methotrexate (VPNTM), or mitoxantrone and ifosfamide … ; etoposide and methotrexate alone (ME); ifosfamide/mesna in combination with mitoxantrone and etoposide (MINE); and others. …

Bidirectional Relationship Between Cancer and Heart Failure: Old and New Issues in Cardio-oncology.

The main focus of cardio-oncology has been the prevention and treatment of the cardiac toxicity of chemotherapy and radiotherapy. Furthermore, several targeted therapies have been associated with unexpected cardiotoxic side-effects. Recently, epidemiological studies reported a higher incidence of cancer in patients with heart failure (HF) compared with individuals without HF. On this basis, it has been proposed that HF might represent an oncogenic condition. This hypothesis is supported by preclinical studies demonstrating that hyperactivation of the sympathetic nervous system and renin-angiot

Совпадение в полном тексте источника
… Alkylating agents, such as cyclophosphamide and ifosfamide, inhibit cell proliferation by inducing DNA damage. … High-dose ifosfamide is associated with severe, reversible cardiac dysfunction. Ann Intern Med. 1993;118:31–6. doi: 10.7326/0003-4819-118-1-199301010-00006. 25. Kurauchi K, Nishikawa T, Miyahara E et al. Role of metabolites of cyclophosphamide in cardiotoxicity. …

Expert consensus: Profiling and management of advanced or metastatic epithelial ovarian cancer.

Introduction and objective: The approach to patients with advanced or metastatic high-grade epithelial ovarian cancer (EOC) has evolved over … ithout bevacizumab. Other agents are considered potentially active (capecitabine, cyclophosphamide, ifosfamide, irinotecan, oxaliplatin, pemetrexed, vinorelbine, cyclophosphamide) could be recommended for later lines. Hormone receptor-positive patients who do not tolerate or have no response to cytotoxic regimens may receive hormone therapy with tamoxifen or …

Therapies and nanotherapies for cervical cancer (Review).

Cervical cancer (CC) is a major global health concern, ranking fourth worldwide in mortality, due to its high death rate and strong link to persistent high-risk human papillomavirus infections, which drive cancer progression through cellular dysregulation. Conventional therapies used in the treatment of CC have significant disadvantages, such as adverse side effects that affect the quality of life of patients. These side effects may include nausea, vomiting, fatigue, hair loss, fertility problems, damage to nearby organs and systemic toxicity. To address these challenges, there has been an inc

Совпадение в полном тексте источника
… , irinotecan, gemcitabine, paclitaxel and topotecan), can be administered alone or in combination Recurrence | • Radiotherapy combined with immunotherapy (pembrolizumab) and/or chemotherapy such as cisplatin, carboplatin, ifosfamide, irinotecan, gemcitabine, paclitaxel, topotecan and vinorelbine | • … Type of drug | Function | Drugs | Type of cancer Alkylating agents | | Nitrogen mustard: Bendamustine, cyclophosphamide and ifosfamide | Lung, breast and ovarian cancer, as well as leukemia, lymphoma, Hodgkin lymphoma, multiple myeloma and sarcoma. …

2023 updated MASCC/ESMO consensus recommendations: prevention of nausea and vomiting following multiple-day chemotherapy, high-dose chemotherapy, and breakthrough nausea and vomiting.

PURPOSE: This review is an update of the MASCC/ESMO 2015 recommendations for the prophylaxis of acute and delayed nausea and vomiting induced by multiple-day chemotherapy, high-dose chemotherapy, and breakthrough nausea and vomiting. METHODS: A systematic literature search was conducted using PubMed from June 1, 2015, through February 1, 2023. RESULTS: We identified 56 references (16 were duplications or invalid), leaving 40 manuscripts for this search. The panel classified level I evidence (three manuscripts) and level II evidence (14 manuscripts). High-dose chemotherapy and stem cell trans

Совпадение в полном тексте источника
… Multiple-day chemotherapy In the present and past, multiple-day chemotherapy studies have included drugs such as dactinomycin, dacarbazine, and ifosfamide. In the prior consensus statements, guidelines only referred to patients with germ cell tumors being treated with multiple-day cisplatin. … NEPA, combined with dexamethasone, was investigated in soft tissue sarcoma patients treated with multiple days of epirubicin and ifosfamide chemotherapy. …

Prognostic and functional role of the nuclear export receptor 1 (XPO1) in gastrointestinal cancers: a potential novel target?

In the last decades the survival of metastatic gastrointestinal (GI) cancer patients could have been significantly extended due to the introduction of targeted- and immunotherapy. However, only the minority of patients will experience long-lasting survival. Hence, novel therapeutics are clearly necessary for GI cancer patients. Molecular high-throughput profiling techniques have revealed potential novel targetable molecular alterations, emphasizing the necessity for tailored therapeutic approaches. Nuclear export proteins, particularly Exportin-1 (XPO1), have emerged as promising targets in ca

Совпадение в полном тексте источника
… Phase II NCT02088541 Acute Myeloid Leukemia (AML) Drug: Selinexor Drug: Hydroxyurea Drug: Ara-C Safety study of KPT-330 (Selinexor) in patients with advanced or metastatic solid tumor cancer Phase I NCT01607905 Solid tumor Drug: Selinexor Drug: Acetaminophen Phase I Trial of Selinexor (KPT-330) and Ifosfamide … 4 week (28-day) a cycle A study of evaluating the safety and efficacy of ATG-010 combined with chemotherapy sequential With ATG-010 monotherapy maintenance in peripheral T- and NK/T-cell lymphoma (TOUCH) Phase I–II NCT04425070 Peripheral T-cell Lymphoma NK/T-cell Lymphoma Combination Product: ICE [ifosfamide …

Keyword Index for Volume 90

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Совпадение в полном тексте источника
… type I (HTLV-I) 2181 hyperlipidaemia 635 hypermethylation 2013 hypermethylation of MGMT 874 hypersensitivity reaction 304 hypoxia 430, 728, 1235, 1429, 1842, 1858 hypoxia inducible factor1 1235 hysterectomy 1756 ibandronate 1133 ICIS 2256 Id-1 overexpression 1198 IDN 5390 1464 IFN- γ 2210 ifosfamide … 1498, 2268 ifosfamide turnover 911 IGF-1 1076 IGF-1R 1825 IHC 471 IL-6 853, 2312 image analysis 430 imaging 2232, 2256 imatinib 2059 immunisation 48 immunogenicity 2402 immunohistochemistry 414, 672, 1052, 1222, 1555, 1572, 1933, 1955, 2197, 2338 immunomodulation 955 immunotherapy 985, …

A Deep Dive Into the Newest Avenues of Immunotherapy for Pediatric Osteosarcoma: A Systematic Review.

Osteosarcoma (OS) is the most common primary bone cancer affecting children and young adults, most often occurring at the metaphysis of long bones. At present, treatment with combinations of surgery and chemotherapy for the localized OS has only brought minuscule improvements in prognosis. In comparison, the advanced, metastatic, or recurrent forms of OS are often non-responsive to chemotherapy, adding to the dire need to develop new and efficient therapies. The question of interest investigated in this systematic review is whether immunotherapy can play a meaningful role in improving the clin

Совпадение в полном тексте источника
… Shortly after introducing surgical resection with adequate margins and combinations of double or triple chemotherapy (i.e., cyclophosphamide and etoposide, gemcitabine and docetaxel, or high-dose methotrexate, etoposide, and ifosfamide) [ 2 ], the survival rate increased immensely [ 3 ]. … Additionally, bevacizumab, a VEGF inhibitor, was combined with either cisplatin, doxorubicin, and high-dose methotrexate, or ifosfamide, etoposide, and high-dose methotrexate, to compare the effects in localized-resectable and metastatic-unresectable OS. …

Clinical management and therapeutic development for the rare disease rhabdomyosarcoma.

Rhabdomyosarcoma (RMS) is a rare disease that arises from skeletal muscle mainly affects children and adolescents. Patients with RMS have diverse symptoms and prognosis based on tumor sizes, tumor anatomical locations, histological subtypes of the tumors and genetic testing of paired-box-forkhead box O1 (PAX-FOXO1) fusion gene. The 4 subtypes of RMS include embryonal RMS (eRMS), alveolar RMS (aRMS), spindle cell/sclerosing RMS (scRMS) and pleomorphic RMS (pRMS). Treatment for RMS patients remains challenging due to its heterogeneous nature. Thus, a combinatory approach is likely to warrant bet

Совпадение в полном тексте источника
… In Europe, the chemotherapy regimen is the combination of ifosfamide, vincristine, and actinomycin D (IVA) 6 . … Cyclophosphamide and ifosfamide react with DNA to interfere DNA replication and cell division. There are no significant differences in the clinical outcomes between VAC and IVA regimens 25 . Table 1 listed the ongoing or completed clinical trials related to RMS. …

Real-World Outcomes of Tisagenlecleucel Versus Standard-of-Care Salvage Chemotherapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A Propensity Score-Matched Analysis From Korea.

BACKGROUND: Tisagenlecleucel, a CD19-directed chimeric antigen receptor T-cell (CAR-T) therapy, has shown durable efficacy in relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL). However, comparative real-world data against standard-of-care (SOC) therapies remain scarce in Asian populations. METHODS: We performed a retrospective, propensity score-matched cohort study at two tertiary hospitals in Korea. Adult patients with R/R DLBCL treated in the third-line (3L) or later setting received either tisagenlecleucel (CAR-T cohort) or SOC salvage chemoimmunotherapy. Propensity score

Совпадение в полном тексте источника
… For the purpose of this study, SOC therapy was defined as salvage chemoimmunotherapy regimens commonly used for relapsed or refractory DLBCL in Korea during the study period (e.g., R-dexamethasone, cytarabine, and cisplatin [DHAP], R-ifosfamide, carboplatin, and etoposide [ICE], gemcitabine, dexamethasone … In the matched SOC cohort, salvage treatment regimens consisted primarily of platinum-based chemotherapy (n = 31), followed by anthracycline-based regimens (n = 11), L-asparaginase–based regimens (n = 2), BR (n = 2), ABVD (n = 2), and IVAM (ifosfamide, etoposide, cytarabine, and methotrexate; n = 2). …

A review of immunotherapy for bone tumors.

This article reviews the latest research progress in immunotherapy for bone tumors. Bone tumors are a serious threat to human health, and traditional treatments have limitations. Recently, immunotherapy, as an emerging treatment method, has shown great potential in the treatment of bone tumors. This article systematically introduces the pathological features, traditional treatment methods and limitations of bone tumors, and focuses on the principles, application status and challenges of immune checkpoint inhibitors, CAR-T cell therapy, tumor vaccines and other immunotherapies. At the same time

Совпадение в полном тексте источника
… Standard treatment for metastatic disease revolves around anthracycline-based chemotherapy, but other drugs including Dacarbazine ( 39 )、Gemcitabine/docetaxel ( 40 )、Ifosfamide ( 41 )、Trabectedin ( 42 )、Pazobanide ( 43 ) and Eribulin ( 44 ) may be used. … Clinical activity and tolerability of a 14-day infusional Ifosfamide schedule in soft-tissue sarcoma . Sarcoma . ( 2013 ) 2013 : 868973 . doi: 10.1155/2013/868973 , PMID: 24369450 PMC3867825 42 Demetri GD von Mehren M Jones RL Hensley ML Schuetze SM Staddon A . …

Severe Acute Kidney Injury in Hospitalized Cancer Patients: Epidemiology and Predictive Model of Renal Replacement Therapy and In-Hospital Mortality.

BackgroundAcute kidney injury (AKI) is a common complication among cancer patients, often leading to longer hospital stays, discontinuation of cancer treatment, and a poor prognosis. This study aims to provide insight into the incidence of severe AKI in this population and identify the risk factors associated with renal replacement therapy (RRT) and in-hospital mortality.MethodsThis retrospective cohort study included 3201 patients with cancer and severe AKI admitted to a Comprehensive Cancer Center between January 1995 and July 2023. Severe AKI was defined according to the KDIGO guidelines as

Совпадение в полном тексте источника
… Notably, antineoplastic treatment accounted for only 17.8% of all cases, with platinum-derived agents being the most frequently implicated class (n = 54), followed by immune checkpoint inhibitors (ICI; n = 52), ifosfamide (n = 12), and tyrosine kinase inhibitors (TKI; n = 6). … Another possible reason is that, since 1995, there have been well-defined protocols and algorithms in our institution, which are regularly reviewed according to the state-of-the-art for prophylaxis of AKI secondary to classical chemotherapy (namely platinum-derived agents and ifosfamide), TLS, contrast …

Body Cavity-Based Lymphoma in a Country with Low Human Immunodeficiency Virus Prevalence: A Series of 17 Cases from the Consortium for Improving Survival of Lymphoma.

PurposePrimary effusion lymphoma (PEL) is a type of body cavity-based lymphoma (BCBL). Most patients with PEL are severely immunocompromised and seropositive for human immunodeficiency virus (HIV). We investigated the distinctive clinicopathologic characteristics of BCBL in a country with low HIV burden.Materials and methodsWe retrospectively collected data on the clinicopathologic characteristics, treatments, and outcomes of 17 consecutive patients with BCBL at nine institutions in Korea.ResultsLatency-associated nuclear antigen 1 (LANA1) immunostaining indicated that six patients had PEL, si

Совпадение в полном тексте источника
… performance status; IPI, international prognostic index; PFS, progression-free sur- vival; OS, overall survival; CHOP, cyclophosphamide, doxorubicin, vincristine, and prednisolone; PR, partial remission; HBV, hepatitis B virus; NA, not assessed or not available; HIV, human immunodeficiency virus; ICE, ifosfamide … 4.1 yr PEL, primary effusion lymphoma; HIV, human immunodeficiency virus. a)The five largest case series of PEL reported thus far (to our knowledge) were used for comparison. 1308 CANCER RESEARCH AND TREATMENT Cancer Res Treat. 2019;51(4):1302-1312 tial diagnosis and was subsequently treated with ifosfamide …

Targeting dorsal root ganglia for chemotherapy-induced peripheral neuropathy: from bench to bedside.

Chemotherapy-induced peripheral neuropathy (CIPN) is a debilitating condition affecting an increasing number of cancer survivors worldwide. However, insights into its pathophysiology and availability of effective therapies remain lacking. Dorsal root ganglia (DRG) have been studied as a key component of chemotherapeutic drug toxicity and a potential therapeutic target for CIPN treatment. This comprehensive review aims to synthesize, summarize, and correlate the results of both preclinical and clinical studies relevant to the pathophysiology and management of CIPN in relation to the DRG. Design

Совпадение в полном тексте источника
… Phase I study of paclitaxel (Taxol) and ifosfamide in previously untreated patients with advanced non-small-cell lung cancer. A study of the National Cancer Institute of Canada Clinical Trials Group. Ann Oncol 1996; 7: 311–313. 138. Patel SR, Vadhan-Raj S, Papadopolous N, et al. … High-dose ifosfamide in bone and soft tissue sarcomas: results of phase II and pilot studies – dose–response and schedule dependence. J Clin Oncol 1997; 15: 2378–2384. 139. Loprinzi CL, Lacchetti C, Bleeker J, et al. …